Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.

ABSTRACT:

Background

Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response.

Objective

The purpose of this study was to analyze disease-free and overall survival.

Design

This was a nonrandomized phase II trial.

Settings

The study was conducted at multiple institutions.

Patients

Four sequential study groups with stage II or III rectal cancer were included.

Intervention

All of the patients received 50 Gy of radiation with concurrent continuous infusion of fluorouracil for 5 weeks. Patients in each group received 0, 2, 4, or 6 cycles of modified FOLFOX6

SUBMITTER: Marco MR 

PROVIDER: S-EPMC6130918 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature